health pharma news today obesity drugs glp-1 The next phase of the drug race A major breakthrough in the
Description
Trulicity sales in 2015 reached $248.7 million and continued to climb to $925.5 million in 2016 and to $2030 million in 2017, taking significant market share away from Victoza (Figure 7, Table 5) [187-189]
We included patients who had been treated with an SGLT2i or GLP-1 RA for at least 6 months and analysed the efficacy, safety and cardio-renal outcomes 5 years after initiation of therapy
More recently in AWARD-10, the addition of dulaglutide to an SGLT2i also resulted in weight loss, reduced HbA1c, and lower systolic blood pressure [94]
While most of the research on GLP-1 and fertility has focused on women, early studies suggest there may be benefits for men as well
In SURMOUNT-1 with non-diabetic participants, the 15mg dose produced that 20.9% figure mentioned above
*FREE* shipping on qualifying offers
